Profile picture of MannKind Corporation

MannKind Corporation

Westlake Village, Los Angeles, CA
2 staff members
2.5 227 Reviews
Company Profile

MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza? (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only orally inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Mission:?To give people control over their health and the freedom to live life.

Company size

201 to 500

Type

Company - Public (MNKD)

Revenue

$10 to $25 million (USD) per year

Industry

Biotech & Pharmaceuticals

Competitors

Eli Lilly and Company, Medtronic, Novo Nordisk

Founded

1991

Staff Members
Worked since Friday, Jun 21 2024
People Also Viewed